Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tramadol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 11/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 13/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.98 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.98 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.98 |
| ▸ | MEN1 | O00255 | 2/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R,R)-Tramadol SCHEMBL29625842 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL429520 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL405854 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL41748 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL7141021 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL1377516 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL405853 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL7137387 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| Tramadol SCHEMBL6052999 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL6543502 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| CN-118127137-A | Method for changing relative amplification speeds of different nucleic acid targets through pre-PCR | 浙江自贸区锐赛生物医药科技有限公司 | 2024-06-04 | — | — | CN | claimed |
| CN-117965705-A | Method for changing relative PCR amplification speed of different nucleic acid targets | 上海锐赛循益生物技术有限公司 | 2024-05-03 | — | — | CN | claimed |
| WO-2003078380-A2 | PROCESS FOR PREPARING TRAMADOL HYDROCHLORIDE AND/OR TRAMADOL MOMOHYDRATE | JUBILANT ORGANOSYS LTD (GB) | 2003-09-25 | — | — | WO | claimed |
| EP-1346978-A1 | Process for preparing tramadol hydrochloride and/or tramadol monohydrate | Jubilant Organosys Limited (IN) | 2003-09-24 | — | — | EP | claimed |
| EP-0831082-B1 | Process for the purification of (RR-SS)-2-dimethylaminomethyl-1-(3-methoxyphenyl)cyclohexanol hydrochloride | CHEMAGIS LTD (IL) | 2002-06-05 | — | — | EP | claimed |
| EP-0778262-B1 | Process for the purification of (RR-SS)-2-dimethyl-aminomethyl-1-(3-methoxyphenyl)cyclohexanol and its salts | CHEMAGIS LTD (IL) | 2001-01-24 | — | — | EP | claimed |
| US-5877351-A | REACTION WITH HYDROGEN BROMIDE | WYCKOFF CHEMICAL COMPANY, INC. (US) | 1999-03-02 | — | — | US | claimed |
| US-5874620-A | ADDING AN ELECTROPHIOLIC REAGENT TO A MIXTURE OF (RR,SS)-TRAMADOL HYDROCHLORIDE AND ITS (RS,SR) GEOMETRICAL ISOMER; REGIOSELECTIVE REACTION WITH THE HYDROXYL GROUP OF THE RS,SR-TRAMADOL LEAVING PURE (RR,SS) ISOMER | CHEMAGIS, LTD. (IL) | 1999-02-23 | — | — | US | claimed |
| EP-0831082-A1 | Process for the purification of (RR-SS)-2-dimethylaminomethyl-1-(3-methoxyphenyl)cyclohexanol hydrochloride | Chemagis Ltd. (IL) | 1998-03-25 | — | — | EP | claimed |
| US-5672755-A | Process for the purification of (RR-SS)-2-dimethyl-aminomethyl-1-(3-methoxyphenyl)cyclohexanol and its salts | CHEMAGIS LTD. (IL) | 1997-09-30 | — | — | US | claimed |
| US-5414129-A | Process for the purification of 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol and its salts | CHEMAGIS, LTD. (IL) | 1995-05-09 | — | — | US | claimed |
| EP-4744652-A2 | A METHOD OF FORMING A COMPOSITION COMPRISING A PROBIOTIC MICRO-ENCAPSULATED IN A DENATURED PLANT PROTEIN MATRIX | Anabio Technologies Limited (IE) | 2026-05-20 | — | — | EP | disclosed |
| US-12616661-B2 | Composition for type II diabetics and for use in providing sustained energy release over time | TEAGASC—The Agriculture and Food Development Authority (IE) | 2026-05-05 | — | — | US | disclosed |
| EP-3972581-B1 | PREBIOTIC COMPOSITIONS | EVONIK OPERATIONS GMBH (DE) | 2026-03-25 | — | — | EP | disclosed |
| US-12582647-B2 | Systems and methods for treating an opioid-induced adverse pharmacodynamic response | PURDUE PHARMA L.P. (US) | 2026-03-24 | — | — | US | disclosed |
| US-5672755-A | Process for the purification of (RR-SS)-2-dimethyl-aminomethyl-1-(3-methoxyphenyl)cyclohexanol and its salts | CHEMAGIS LTD. (IL) | 1997-09-30 | — | — | US | disclosed |
| EP-0778262-A2 | Process for the purification of (RR-SS)-2-dimethyl-aminomethyl-1-(3-methoxyphenyl)cyclohexanol and its salts | Chemagis Ltd. (IL) | 1997-06-11 | — | — | EP | disclosed |
| US-5414129-A | Process for the purification of 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol and its salts | CHEMAGIS, LTD. (IL) | 1995-05-09 | — | — | US | disclosed |
| US-5414129-A | Process for the purification of 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol and its salts | CHEMAGIS, LTD. (IL) | 1995-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582647-B2 | Systems and methods for treating an opioid-induced adverse pharmacodynamic response | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885SLC6A2 10/4885SLC6A4 14/4885 |
| US-12616661-B2 | Composition for type II diabetics and for use in providing sustained energy release over time | GIPR, GLP1R, GPR119 | OPRM1 3095/4885SLC6A2 2391/4885SLC6A4 2410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.